ArticleFrontiers in cellular and infection microbiology2026
Broad-spectrum antiviral activity of the synthetic rocaglate zotatifin against Mayaro virus and other viruses.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses pose a significant threat to global public health, yet therapeutic options remain limited. Zotatifin, a synthetic rocaglate targeting eukaryotic initiation factor 4A (eIF4A), inhibits viral protein synthesis and potentially triggers interferon responses; however, its broad-spectrum antiviral potential remains unclear. We evaluated zotatifin's cytotoxicity using MTT assays and assessed its antiviral activity through plaque-forming assays, Western blot analysis, immunofluorescence, and flow cytometry across multiple cell lines and virus strains. Zotatifin demonstrated superior tolerability compared to rocaglamide A and CR-1-31-B. The compound exhibited potent, dose-dependent inhibition of Mayaro virus, achieving a >4-log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.